- Home
- CAPR vs EBTC Comparison
CAPR vs EBTC Comparison
Compare CAPR & EBTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- EBTC
- Stock Information
- Founded
- CAPR 2005
- EBTC 1989
- Country
- CAPR United States
- EBTC United States
- Employees
- CAPR N/A
- EBTC N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- EBTC Major Banks
- Sector
- CAPR Health Care
- EBTC Finance
- Exchange
- CAPR Nasdaq
- EBTC Nasdaq
- Market Cap
- CAPR 525.3M
- EBTC 492.5M
- IPO Year
- CAPR N/A
- EBTC 2005
- Fundamental
- Price
- CAPR $9.48
- EBTC $38.89
- Analyst Decision
- CAPR Strong Buy
- EBTC
- Analyst Count
- CAPR 7
- EBTC 0
- Target Price
- CAPR $39.29
- EBTC N/A
- AVG Volume (30 Days)
- CAPR 1.5M
- EBTC 34.2K
- Earning Date
- CAPR 03-19-2025
- EBTC 04-22-2025
- Dividend Yield
- CAPR N/A
- EBTC 2.57%
- EPS Growth
- CAPR N/A
- EBTC 0.32
- EPS
- CAPR N/A
- EBTC 3.12
- Revenue
- CAPR $22,270,465.00
- EBTC $168,758,000.00
- Revenue This Year
- CAPR $34.33
- EBTC N/A
- Revenue Next Year
- CAPR $246.72
- EBTC N/A
- P/E Ratio
- CAPR N/A
- EBTC $12.48
- Revenue Growth
- CAPR N/A
- EBTC 4.53
- 52 Week Low
- CAPR $3.52
- EBTC $22.60
- 52 Week High
- CAPR $23.40
- EBTC $44.41
- Technical
- Relative Strength Index (RSI)
- CAPR 33.11
- EBTC 40.58
- Support Level
- CAPR $12.64
- EBTC $38.19
- Resistance Level
- CAPR $13.81
- EBTC $41.69
- Average True Range (ATR)
- CAPR 1.18
- EBTC 0.91
- MACD
- CAPR -0.32
- EBTC 0.03
- Stochastic Oscillator
- CAPR 9.83
- EBTC 20.00
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About EBTC Enterprise Bancorp Inc
Enterprise Bancorp Inc is a holding company engaged in the business of gathering deposits from the general public and investing in loans and investment securities. Through the Bank and its subsidiaries, the company offers a range of commercial, residential, and consumer loan products, deposit products, and cash management services, as well as wealth management and wealth services.